RecruitingPhase 2NCT05871970
Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age
Studying Macrocystic lymphatic malformation
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Protara Therapeutics
- Principal Investigator
- Chief Scientific Operations OfficerProtara Therapeutics
- Intervention
- TARA-002(biological)
- Enrollment
- 38 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (10)
- Children's Hospital of Alabama, Birmingham, Alabama, United States
- Arkansas Children's Hospital/UAMS, Little Rock, Arkansas, United States
- Children's Hospital of Colorado, Aurora, Colorado, United States
- Children's National Medical Center: Children's Research Institute, Washington D.C., District of Columbia, United States
- Nemours Children's Clinic - Jacksonville, Jacksonville, Florida, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Oregon Health & Science University, Portland, Oregon, United States
- Children's Hospital of Philadelphia: Comprehensive Vascular Anomalies Program, Philadelphia, Pennsylvania, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- Children's Hospital of the King's Daughters, Norfolk, Virginia, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05871970 on ClinicalTrials.gov